Vicuron Pharmaceuticals Obtains Patent for Dalbavancin Dosing

The U.S. Patent and Trademark Office has issued Vicuron Pharmaceuticals a patent covering a novel dosing regimen for dalbavancin.

The patent, titled "Methods of Administrating Dalbavancin for Treatment of Bacterial Infections," will expire in December 2023. Vicuron is seeking FDA approval for dalbavancin as a treatment for complicated skin and soft-tissue infections.